Progyny's third-quarter revenue rose 8.9% to $341.25 million, slightly above analyst expectations, while adjusted EBITDA of $58.44 million also slightly beat consensus. The company raised the midpoint of its 2026 guidance, forecasting revenue of $1.365 billion to $1.385 billion and net income of $107 million to $110.6 million.
Progyny reported third-quarter revenue of $341.25 million, up 8.9% and slightly above the $340.92 million analyst consensus. Adjusted EBITDA was $58.44 million, compared with the $57.94 million consensus; net income was $26.25 million and earnings per share were $0.32.
The company raised the midpoint of its full-year 2026 guidance and expects revenue of $1.365 billion to $1.385 billion and net income of $107 million to $110.6 million.
Progyny said revenue growth was driven by an increase in clients and covered lives. Higher gross profit reflected improved care management efficiencies and lower stock-based compensation expense, partly offset by planned investments in platform features. The company repurchased nearly 3 million shares in the quarter and nearly 11 million in 2026.
